Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Grace Therapeutics, Inc.

NASDAQ: GRCE · Life Sciences · 9 alerts · CIK 1444192

Share price
$1.75Close, Nov 16
Market cap
$36.8M
Shares outstanding
21.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Grace Therapeutics, Inc. filings on SEC EDGAR ↗

8:01 AM ET 8-K
Financial Results

Grace Therapeutics Financial Results

Grace Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $2.1 million. The company is currently focused on resubmitting its New Drug Application (NDA) for GTx-104 after addressing CMC and non-clinical items identified by the FDA. Management noted that a recent $10 million financing has extended the company's cash runway through the end of 2028.

“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104.”

Prashant Kohli, Chief Executive Officer

“The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission.”

Prashant Kohli, Chief Executive Officer
7:32 AM ET 10-Q
Financial Results

Grace Therapeutics Q2 2026 Results: Net Loss of $2.13M, Loss Widens

Grace Therapeutics reported a net loss of $17.9 million for the six months ended September 30, 2026, primarily driven by a $13.5 million impairment of intangible assets related to GTx-102 and GTx-101. The company strengthened its liquidity through a $9.2 million private placement in August 2026, providing sufficient cash to fund operations for at least 12 months.

Key figure
Net loss $2.13M
9:06 PM ET Form 4
Insider Buying

Grace Therapeutics Insider Opaleye Management Inc. Buys $18.5K of Stock

Opaleye Management Inc. bought 10,328 shares of Grace Therapeutics, Inc. at $1.79 a share, worth $18.5K in total on Nov 3, 2026. Shares held after the trade: 3,046,739 (+0.3%).

Value
$18.5K
Shares
10,328
Price
$1.79
Holding change
+0.3%
Trade date
Nov 3, 2026
6:06 PM ET Form 4
Insider Buying

Grace Therapeutics Insider Opaleye Management Inc. Buys $159K of Stock

Opaleye Management Inc. bought 87,801 shares of Grace Therapeutics, Inc. at $1.77 to $1.93 a share (average $1.81) in 2 transactions, worth $159K in total between Oct 22, 2026 and Oct 26, 2026. Shares held after the trade: 3,036,411 (+2.2%).

Value
$159K
Shares
87,801
Average price
$1.81
Holding change
+2.2%
Trade date
Oct 22, 2026 to Oct 26, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.